New approach for management of impotence

ABSTRACT

A new type of topically applied drug [Eroderm-3 cream] for impotence was presented. Eroderm-3 cream contains vasoactive drug that had the ability to penetrate the penile cutaneous issue and facilitate erection. In this study, the usefulness of Eroderm-3 was examined in the treatment of erectile dysfunction. Eroderm-3 contains co- dergocrine mesilate, aminophylline and isosorbide dinitrate. A randomized double-blind controlled trial on 36 patients was performed after the etiology of impotence was investigated. All patients received Eroderm-3 and placebo cream. The patients were randomly divided into two groups each of eighteen patients. The first group received Eroderm-3 in the first month and placebo cream in the second month, while the second group received placebo in the first month and Eroderm-3 in the second month. The patients were advised to apply the cream on the penile shaft quarter of an hour before sexual stimulation and intercourse. The patients reported their experience via questionnaire. Twenty-one patients reported full erection and satisfactory intercourse, two patients reported partial erection and four patients reported just tumescence. Three patients reported full erection and satisfactory intercourse with either cream, while neither Eroderm-3 nor placebo cream produced a noticeable response in nine patients. The highest activity proved to occur in psychogenic impotence, while less rate of success was observed in patients with venous leakage. Laboratory testing of Eroderm-3 showed a high activity in increasing penile arterial flow and induced tumescence in 61% of patients. No marked side effects were recorded